Stakeholder Insight: Osteoarthritis - Drug development lags behind rising osteoarthritis population

Datamonitor expect osteoarthritis prevalence to grow by over 10 million by 2020, owing mainly to an aging population. In the near-term the approach to treatment will remain constant, with improved side-effects dominating the unmet needs. However, therapies which target the underlying causes of osteoarthritis have the potential to reshape osteoarthritis treatment.

The estimated diagnosis rate of 55% reflects a lack of treatment-seeking by mild sufferers of the disease, who often resort to self-medication. This equates to nearly 37 million undiagnosed patients in 2009 and with a predicted rise in osteoarthritis numbers this is a market with growth potential.

Pain-relieving drugs, particularly, oral non-steroidal anti-inflammatory drugs (NSAIDs) are the foundation of pharmacological therapy in osteoarthritis. Physicians continue to be concerned over NSAID toxicity, with three-quarters of severe patients who are receiving NSAIDs currently co-prescribed a gastroprotectant.

Physicians are generally unsatisfied with current osteoarthritis pharmacological treatments. A clear need for alternative drugs exists to treat this prevalent condition. 41% of physicians ranked disease modifying osteoarthritis drugs (DMOADs) as the highest unmet need, but the majority of physicians estimate that DMOADs are 8 years from the market.

Read more...

Comments

Add New Search RSS

Write comment
Name:
Email:	do not notifynotify
Website:
Title:
	Please input the anti-spam code that you can read in the image.

Powered by !JoomlaComment 3.26

3.26 Copyright (C) 2008 Compojoom.com / Copyright (C) 2007 Alain Georgette / Copyright (C) 2006 Frantisek Hliva. All rights reserved."

• Innovative Arthritis Medicine (09/06/2010)
• NicOx (14/05/2010)
• Osteoarthritis (26/05/2008)

• Drug Delivery (06/04/2010)
• Pharmaceutical Key Trends 2010 (06/04/2010)
• Infant Care (06/04/2010)

• Medical Imaging (15/02/2010)
• Ultrasound Systems Market (15/02/2010)
• Global Hip And Knee Implants (15/02/2010)
• Remote Patient Monitoring (15/02/2010)
• Europe Orthopedic Biomaterials (15/02/2010)
• Cardiac Assist Devices (15/02/2010)
• Alzheimer?s Disease (15/02/2010)
• Attention Deficit Hyperactivity Disorder (15/02/2010)
• Acute Ischemic Stroke (15/02/2010)

---